Hepatitis C virus epitopes
AssigneeGenelabs Technologies, Inc.
InventorsGregory R. Reyes, Jungsuh P. Kim, Randolph Moeckli, Christian C. Simonsen
Life of this patent
Estimating the term…
Abstract
Peptide antigens which are immunoreactive with sera from individuals infected with hepatitis C virus (HCV) are disclosed. Several of the antigens are immunologically reactive with antibodies present in individuals identified as having chronic and acute HCV infection. The antigens are useful in diagnostic methods for detecting HCV infection in humans. Also disclosed are corresponding genomic-fragment clones containing polynucleotides encoding the open reading frame sequences for the antigenic peptides.
Claims5
A recombinant polypeptide which is specifically immunoreactive with sera from humans infected with hepatitis C virus (HCV), where said polypeptide has the peptide sequence presented as SEQ ID NO:10.
A diagnostic kit for use in screening human blood containing antibodies specific against hepatitis C virus (HCV) infection comprising
- at least one peptide antigen which is immunoreactive with sera from humans infected with hepatitis C virus (HCV), where said peptide antigen has the peptide sequence presented as SEQ ID NO:10, and
- means for detecting the binding of said antibodies to the antigen.
A method of detecting hepatitis C virus (HCV) infection in an individual comprising
- reacting serum from an HCV-infected test individual with a peptide antigen which is specifically immunoreactive with sera from humans infected with hepatitis C virus (HCV), where said peptide antigen has the peptide sequence presented as SEQ ID NO:10, and
- examining the antigen for the presence of bound antibody.
Dependencies are inferred from the claim text.